SCHEMBL4898170

SCHEMBL4898170

COc1cc(Cl)cc(-c2nc(SC)nc(O)c2C#N)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ADORA1 P30542 9/20 0.42
ADORA2A P29274 7/20 0.42
ADORA2B P29275 4/20 0.42
MAPT P10636 3/20 0.41
RXFP1 Q9HBX9 3/20 0.41
KDM1A O60341 1/20 0.38
PIM1 P11309 1/20 0.38
HPGD P15428 4/20 0.37
ALDH1A1 P00352 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 2/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907415 0.88 KMT2A (0.57) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4421002 0.82 RXFP1 (0.61) KMT2AADORA1ADORA2AADORA2BMAPT
SCHEMBL4905668 0.80 KDM1A (0.44) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4906699 0.79 ALDH1A1 (0.47) KMT2AADORA1ADORA2AADORA2BMAPT
SCHEMBL4911158 0.75 PIM1 (0.41) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4903971 0.75 KMT2A (0.53) KMT2ACYP1A2CYP2C9CYP2C19MAPT
SCHEMBL4907554 0.74 CCR1 (0.44) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4420483 0.72 RXFP1 (0.61) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4900833 0.72 KMT2A (0.56) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL18893661 0.68 RXFP1 (0.67) KMT2AADORA1ADORA2AADORA2BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF KMT2A 3422/4885CYP1A2 1768/4885CYP2C9 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.